Protalix BioTherapeutics (PLX) Stock Analysis & AI Equity Report
Protalix BioTherapeutics (PLX) overview
Protalix BioTherapeutics (PLX) stock analysis and AI equity research. For financial year 2025, Valuatum's model shows revenue of USD 52.7m and operating profit of USD -5.5m; the year-end share price was 1.80 USD and market capitalisation was USD 145m. Protalix BioTherapeutics is covered by Valuatum but does not yet have a published AI equity report. Generate a fresh report to get Protalix BioTherapeutics's valuation, segment value analysis, reverse valuation, financial forecasts, key ratios, risks and catalysts.
Key metrics & valuation multiples
About Protalix BioTherapeutics
Protalix BioTherapeutics discovers, develops, produces, and commercializes treatments for rare diseases using its plant cell-based protein expression platform and other approaches. Its commercial products include enzyme replacement therapies for Gaucher and Fabry diseases. The company sells Elelyso drug substance to licensees Pfizer and Fiocruz, and manufactures Elfabrio for Chiesi, which handles its global commercialization and distribution.
Generate the Protalix BioTherapeutics report
Protalix BioTherapeutics is on Valuatum's coverage list, but a full AI equity report hasn't been generated yet. Order one now for the complete company value map, reverse valuation, risk & catalyst analysis, and financial statements and estimates — plus a downloadable PDF.
Sources & methodology
Financial figures are sourced from Valuatum's financial model for Protalix BioTherapeutics and represent financial year 2025. See the methodology for the full Valuatum AI equity research framework.
Disclaimer: This is an AI-generated research material for informational purposes only. It is not investment advice or a buy/sell recommendation. Always perform your own analysis. Valuatum Oy, Helsinki, Finland.
Analyst reports on Protalix BioTherapeutics
Each report here is this company's Valuatum report re-run with an analyst's own assumptions and published under their name. They are ordered by a score out of five: what other analysts felt the work added over the engine's default report.